These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 327556)
1. The conduct of therapeutic trials in cancer medicine. Rudnick S; Capizzi RL Semin Oncol; 1977 Jun; 4(2):255-8. PubMed ID: 327556 [No Abstract] [Full Text] [Related]
2. Ethical issues in cooperative cancer therapy trials from a statistical viewpoint. II. Specific issues. Shuster JJ; Krischer JP; Boyett JM Am J Pediatr Hematol Oncol; 1985; 7(1):64-70. PubMed ID: 4037245 [TBL] [Abstract][Full Text] [Related]
3. Clinical development of anticancer agents--a National Cancer Institute perspective. Marsoni S; Wittes R Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870 [No Abstract] [Full Text] [Related]
4. The last patient in a drug trial. Hastings Cent Rep; 1981 Dec; 11(6):21-3. PubMed ID: 7333839 [No Abstract] [Full Text] [Related]
5. Non-randomized controls in cancer clinical trials. Gehan EA; Freireich EJ N Engl J Med; 1974 Jan; 290(4):198-203. PubMed ID: 4587632 [No Abstract] [Full Text] [Related]
7. Phase I cancer trials: therapeutic research? Kodish E Hastings Cent Rep; 2001; 31(1):4-5. PubMed ID: 11478093 [No Abstract] [Full Text] [Related]
8. Cancer drug approval in the United States, Europe, and Japan. Milsted RA Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686 [No Abstract] [Full Text] [Related]
9. The ethical approach to phase I clinical trials in oncology. Durry G; Dion S Drugs Exp Clin Res; 1986; 12(1-3):21-2. PubMed ID: 3732049 [No Abstract] [Full Text] [Related]
10. The ethical approach to phase II clinical trials in oncology. Dion S Drugs Exp Clin Res; 1986; 12(1-3):41-2. PubMed ID: 3732053 [No Abstract] [Full Text] [Related]
11. Phase 0 trials: are they ethically challenged? Hill TP Clin Cancer Res; 2007 Feb; 13(3):783-4. PubMed ID: 17289866 [No Abstract] [Full Text] [Related]
12. Improving the evaluation of new cancer treatments: challenges and opportunities. Rothenberg ML; Carbone DP; Johnson DH Nat Rev Cancer; 2003 Apr; 3(4):303-9. PubMed ID: 12671669 [TBL] [Abstract][Full Text] [Related]
14. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846 [TBL] [Abstract][Full Text] [Related]
15. Historical background of the National Cancer Institute's drug development thrust. Zubrod CG; Schepartz SA; Carter SK Natl Cancer Inst Monogr; 1977 Mar; (45):7-11. PubMed ID: 337156 [No Abstract] [Full Text] [Related]
16. [40 years of progress in chemotherapy]. Cvitkovic-Bertheault F Pathol Biol (Paris); 2000 Nov; 48(9):812-8. PubMed ID: 11141916 [TBL] [Abstract][Full Text] [Related]
17. [Phase II therapeutic trials in Cancerology: what's new? For a better multicenter and multidisciplinary cooperation]. Pignon JP Gastroenterol Clin Biol; 1992; 16(2):131-3. PubMed ID: 1568539 [No Abstract] [Full Text] [Related]
18. Design and analysis of non-inferiority mortality trials in oncology. Carroll K; Milsted B; Lewis JA Stat Med; 2004 Sep; 23(17):2771-4; author reply 2774-8. PubMed ID: 15316946 [No Abstract] [Full Text] [Related]
19. Recent advances in cancer chemotherapy. Speechley V Nursing (Lond); 1987 Aug; 3(20):743-7. PubMed ID: 3313128 [No Abstract] [Full Text] [Related]
20. Methodologic considerations for trials of lung cancer prophylaxis. Miller AB Can Med Assoc J; 1980 Apr; 122(7):776-9. PubMed ID: 7363245 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]